The Technical Analyst
Y-mAbs Therapeutics, Inc [YMAB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Y-mAbs Therapeutics, Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.73% $15.00
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 656.66 mill |
| EPS: | -0.490 |
| P/E: | -30.61 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 43.78 mill |
| Avg Daily Volume: | 0.388 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -30.61 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -5.21x |
| Company: PE -30.61 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 13.85 - 16.15 ( +/- 7.65%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-12 | Tagliaferri Mary | Buy | 27 900 | Stock Option (right to buy) |
| 2024-03-12 | Tagliaferri Mary | Buy | 4 660 | Common Stock |
| 2024-02-29 | Tagliaferri Mary | Buy | 0 | |
| 2024-03-05 | Rajah Vignesh | Sell | 1 711 | Common Stock |
| 2024-03-05 | Gad Thomas | Sell | 3 900 | Common Stock |
| INSIDER POWER |
|---|
| 77.72 |
| Last 98 transactions |
| Buy: 3 651 211 | Sell: 357 293 |
Forecast:
16:00 - $15.00
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $15.00
Forecast 2: 16:00 - $15.00
Forecast 3: 16:00 - $15.00
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $15.00 (-0.73% ) |
| Volume | 0.398 mill |
| Avg. Vol. | 0.388 mill |
| % of Avg. Vol | 102.79 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For YMAB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $13.04 | N/A | Active |
|---|
YMAB
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Latest Press Releases
2024-03-14 09:05:00 - Press Release
Y-mabs Therapeutics Announces Resignation Of Chief Financial Officer
New york, march 14, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that chief financial officer, bo kruse, has notified the company of his resignation. y-mabs has commenced a search process for a successor. mr. kruse will remain in the chief financial officer role until his successor is identified and joins the company. he will then continue as a non-executive employee from the time his successor joins the company through july 31, 2024, after which it is expected that mr...
2024-03-04 07:30:00 - Press Release
Y-mabs Appoints Oncology Executive Mary Tagliaferri, M.d. To Its Board Of Directors
Dr. tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development dr. tagliaferri brings deep biopharmaceutical industry expertise and a successful track record in oncology therapeutic development
2024-02-29 16:05:00 - Press Release
Y-mabs Reports Fourth Quarter And Full Year 2023 Financial Results And Recent Corporate Developments
New york, feb. 29, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the quarter and full year ended december 31, 2023.
2024-02-16 07:30:00 - Press Release
Y-mabs To Announce Fourth Quarter And Full Year 2023 Financial And Operating Results On February 29, 2024
New york, feb. 16, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab) today announced that it will report its financial results for the quarter and full year ended december 31, 2023, on thursday, february 29, 2024, after the close of the u.s. financial markets. the announcement will be followed by a conference call and webcast with the investment community on friday, march 1, 2024, at 8:00 a.m. et. participating on the call from y-mabs will be michael rossi, president and chief executive officer; bo kruse, chief financial officer; sue smith, chief commercial officer; vignesh rajah, chief medical officer; thomas gad, founder, vice chair and chief business officer; and steen lisby, chief scientific officer.
2024-01-02 16:05:00 - Press Release
Y-mabs Therapeutics To Present At 42nd Annual J.p. Morgan Healthcare Conference
New york, jan. 02, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that michael rossi, president and chief executive officer, will present at the 42nd annual j.p. morgan healthcare conference in san francisco, ca on wednesday, january 10, 2024 at 5:15pm pt.
Latest News
2024-04-17 08:30:31 - Zacks Investment Research
New Strong Buy Stocks for April 17th
BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
2024-03-28 10:56:11 - Zacks Investment Research
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in YmAbs Therapeutics (YMAB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
2024-03-20 08:40:14 - Zacks Investment Research
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
YmAbs Therapeutics (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
2024-03-12 10:55:15 - Zacks Investment Research
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
The consensus price target hints at a 31.4% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-05 13:01:35 - Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
Does Y-mAbs Therapeutics, Inc. (YMAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-29 18:26:07 - Zacks Investment Research
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.03 per share a year ago.
2024-02-22 11:05:26 - Zacks Investment Research
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-02-16 07:30:00 - GlobeNewsWire
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter and full year ended December 31, 2023, on Thursday, February 29, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, March 1, 2024, at 8:00 a.m. ET. Participating on the call from Y-mAbs will be Michael Rossi, President and Chief Executive Officer; Bo Kruse, Chief Financial Officer; Sue Smith, Chief Commercial Officer; Vignesh Rajah, Chief Medical Officer; Thomas Gad, Founder, Vice Chair and Chief Business Officer; and Steen Lisby, Chief Scientific Officer.
2024-02-13 05:11:07 - Zacks Investment Research
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2024-01-02 16:05:00 - GlobeNewsWire
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 5:15pm PT.